AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03477201 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparoscopic robotic DaVinci assisted inguinal hernia repair
Description: Laparoscopic inguinal hernia repair using a robotic assisted laparoscopic procedure.
Study NCT03477201 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard laparoscopic inguinal hernia repair
Description: Laparoscopic inguinal hernia repair, an accepted safe method of repairing inguinal hernia.
Study NCT01938430 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LDV/SOF
Description: LDV/SOF FDC tablet administered orally once daily
Study NCT01837719 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cobicistat
Description: 150-mg tablet
Study NCT01837719 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atazanavir/Cobicistat FDC
Description: Atazanavir 300-mg/cobicistat 150-mg FDC tablet
Study NCT03606850 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Measurements of markers of cortical excitability by TMS
Description: In the arm experimental treatment by citalopram, measurements of markers of cortical excitability by Transcranial Magnetic Stimulation will be applied. These measurements were: the cortical silent period CSP, the evoked potential MEP, the intra-cortical inhibition ICI and the intra-cortical facilitation ICF). Electromagnetic coil is placed upon the vertex, according to the International 10-20 EEG system. Gathering of the peripheral signal by a surface EMG electrode (non invasive device) placed regarding one of the first dorsal interosseous muscle.
Study NCT01162564 — intervention group
Intervention type: DEVICE
Intervention: NG-TSM
Description: Flexible Composite Next Generation Tissue Separating Mesh
Study NCT03326050 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Gemifloxacin
Description: Gemifloxacin 320Mg Oral Tablet once daily
Study NCT03326050 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ciprofloxacin
Description: cipro 750 tablet twice daily
Study NCT03326050 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Rifampicin
Description: Rifampicin 150Mg Capsule twice daily
Study NCT01995318 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Kinesiotaping
Description: Application of anti-edema type kinesiotaping to injured ankle.
Study NCT01938430 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RBV
Description: RBV tablets administered orally in a divided daily dose
Study NCT02887430 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: foot reflexology therapy
Description: standard care and foot reflexology
Study NCT00674570 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydrocortisone
Description: 25 mg/oral one hour prior to extinction task
Study NCT00674570 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D-Cycloserine
Description: 50 mg/oral one hour prior to extinction task
Study NCT00674570 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: One hour prior to extinction task
Study NCT03472456 — intervention group
Intervention type: DRUG
Intervention: Implementation of a pulp medication in compliance with the dental emergency management protocol: articaïne
Description: Implementation of a pulp medication in compliance with the dental emergency management protocol: articaïne
Study NCT03472456 — intervention group
Intervention type: DRUG
Intervention: Implementation of a pulp medication in compliance with the dental emergency management protocol: eugenol
Description: Implementation of a pulp medication in compliance with the dental emergency management protocol: eugenol
Study NCT02228395 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04958242
Description: Administered as specified in treatment arm
Study NCT02228395 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Administered as specified in treatment arm
Study NCT04203043 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pycnogenol Oral Product
Description: pycnogenol use to prevent hyper pigmentation after foam sclerotherapy
Study NCT04203043 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT02426723 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phase 1a: CWP232291
Description: CWP232291 administered alone twice weekly every 4 weeks.
Study NCT02426723 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phase 1b: CWP232291, Lenalidomide, Dexamethasone
Description: CWP232291 administered twice weekly every 4 weeks. Lenalidomide and Dexamethasone administered per standard therapy.
Study NCT02953743 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib
Description: Lenvatinib 4 mg capsules will be administered orally, once daily continuously 28-day cycles until disease progression, development of unacceptable toxicity or withdrawal of consent.
Study NCT01889186 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-199 (Main Cohort)
Description: Participants received a test dose of ABT-199 of ≤ 20 mg on Week 1 Day 1 of the Lead-In Period. For those with significant electrolyte and/or lymphocyte changes within 24 hours of the first dose, the 20 mg dose was maintained for 7 days with escalation to 50 mg on Week 2 Day 1. If none of the electrolyte and/or lymphocyte changes occurred within 24 hours from ABT-199 20 mg dose administration, the participant was dose-escalated to 50 mg on Week 1 Day 2. After the first dose of 50 mg, if no laboratory abnormalities occurred, the participant remained on the 50 mg dose through Week 1. After receiving the 50 mg dose for approximately 1 week (6 to 7 days), the following dose escalation proceeded with weekly increases in dose: → 100 mg → 200 mg → 400 mg (or additional lead-in steps to designated 400 mg dose), as tolerated.
Study NCT01889186 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-199 (Safety Expansion Cohort)
Description: Participants received an initial dose of ABT-199 of 20 mg on Week 1 Day 1 of the Lead-In Period. If one or more electrolyte changes (from the 0 hr measurement prior to dosing) suggestive of laboratory tumor lysis syndrome (LTLS) or clinical TLS (CTLS) occurred within 24 hours of the 20 mg dose, no additional doses were administered until resolution. Upon resolution of laboratory abnormalities, the 20 mg dose was continued through Week 1. If no significant findings suggestive of clinical or laboratory TLS occurred within 24 hours, the 20 mg dose was continued through Week 1 Day 7, and escalated to a dose of 50 mg on Week 2 Day 1. Those who had drug interruptions may have been allowed to escalate to and be maintained at 50 mg for 1 week after they had been on a 20 mg dose for at least 1 week (5 - 7 days). After a week at 50 mg, weekly dose escalations were implemented as follows: 100 mg → 200 mg → 400 mg (or additional lead-in steps to designated 400 mg dose) as tolerated.
Study NCT01208298 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cold Sore Patch
Description: All eligible subjects received CSP-Night at Screening Visit 1. Subjects were instructed to initiate therapy within approximately 1 hour of onset of their first sign or symptom. Treatment was continued until the lesion healed, or for a maximum of 10 days. All subjects were expected to return to the study center for clinical assessments within 24 hours and 48 hours after initiating treatment, and every other day thereafter, with a final visit at Day 10 or at the time of completion/ discontinuation if before Day 10.
Study NCT01166516 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Treatment with HUD IBV Valve System
Description: Treatment involves placing one or more valves in the airways of the lung to control a prolonged air leak.
Study NCT03262740 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986195
Description: Oral administration of specified dose on specified days
Study NCT03262740 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Loestrin 1.5/30 (1.5 mg norethindrone acetate/30 μg ethinyl estradiol)
Description: Oral Contraceptive
Study NCT00286117 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anastrozole
Description: oral
Study NCT00286117 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tamoxifen
Description: oral
Study NCT03956290 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: TREAT pilot intervention
Description: Participants will be asked to use the app and take pictures of everything they eat and drink, from the time they get up to the time they go to bed, regardless of size of meal/snacks/drink, for 2 weeks. This will generate data on their eating pattern and eating duration. Participants will be reminded through app, call or text by study staff based on personalized eating schedule. The sleep schedule will also be recorded.
Study NCT03364855 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Star excursion balance test
Description: Star excursion balance test,
Study NCT03364855 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Kinesthetic Ability Trainer 2000
Description: Kinesthetic Ability Trainer 2000
Study NCT03364855 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: SEBT and KAT 2000
Description: Star excursion balance test and Kinesthetic Ability Trainer 2000
Study NCT01933451 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Intraoperative fluid therapy
Description: Intraoperative fluid therapy is directed by pulse pressure variation to a setting value, above 18% or below 13%.
Study NCT01933451 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intraoperative fluid therapy
Description: Intraoperative fluid therapy is directed by pulse pressure variation to a setting value, above 18% or below 13%.
Study NCT01227603 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nifedipine-candesartan FDC (BAY 98-7106)
Description: Single dose of 1 FDC tablet consisting of 60 mg nifedipine GITS and 32 mg candesartan
Study NCT01227603 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nifedipine GITS (Adalat LA, BAYA1040)
Description: Single oral dose of 1 tablet of nifedipine GITS 60 mg
Study NCT01227603 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Candesartan (Atacand)
Description: Single oral dose of 32 mg (2 x 16 mg tablet) candesartan
Study NCT00732186 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: IV Solution, IV, 10 mg/kg, (if dose reduction necessary at 3 mg/kg), Every three weeks for the first 10 weeks, with a booster at week 22, Up to 38 weeks depending on response
Study NCT01321541 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pixantrone + Rituximab
Description: Pixantrone + Rituximab: Rituximab 375 mg/m2 IV on day 1 and pixantrone 50 mg/m2 (equivalent to 85mg/m2 pixantrone dimaleate)IV on days 1, 8, and 15. Regimen is given in 28-day cycles. Up to 6 cycles may be administered.
Study NCT01321541 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine + Rituximab
Description: Gemcitabine + Rituximab: Rituximab 375 mg/m2 IV on day 1 and gemcitabine 1000 mg/m2 IV on days 1, 8, and 15. Regimen is given in 28-day cycles. Up to 6 cycles may be administered.
Study NCT04496999 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HDM201
Description: Dose level 0: HDM201 40 mg QD d1,2 (midday)/ Dose level 1: HDM201 40 mg QD d1,2,3 (midday) = Starting dose/ Dose level 2: HDM201 40 mg QD d1,2,3,4,5 (midday)/ Dose level 3: HDM201 60 mg QD d1,2,3,4,5 (midday)/ Dose level 4: HDM201 80 mg QD d1,2,3,4,5 (midday)
Study NCT04496999 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midostaurin
Description: Midostaurin 50mg bid d1-28 (morning, evening)
Study NCT04131530 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: The diagnosis of Artificial Intelligence and endoscopist
Description: When the colon mucosa is observed using pCLE, endoscopist and AI will make a diagnosis independently. In addition, the endoscopist can not see the diagnosis of AI.
Study NCT03223532 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PrePex Day 7 FRP
Description: Standard PrePex procedure, foreskin and device are removed 1 week after device application.
Study NCT03223532 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PrePex Day 0 FRP
Description: Removal of the foreskin shortly after device application, the device is removed 1 week later
Study NCT00688285 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: automated clinical alerts
Description: automated clinical alerts in the electronic medical record
Study NCT00688285 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: provider education
Description: PCP education session on CKD
Study NCT03842943 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Preoperative infusions
Study NCT03842943 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Talimogene Laherparepvec
Description: Preoperative intralesional injection
Study NCT01051609 — intervention group
Intervention type: OTHER
Intervention: History and Physical Exam
Description: The physical exam includes vital signs and ECOG performance status.
Study NCT03554148 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: This is purely an observational study. Groups SSI/No SSI are defined by the occurence of a surgical site infection.
Study NCT01625819 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tai Chi
Description: 32 1-hour bi-weekly group sessions of Tai Chi instruction
Study NCT01625819 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Resistance Band
Description: 32 1-hour bi-weekly group sessions of Resistance Band exercises
Study NCT01625819 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Health Education
Description: 32 1-hour bi-weekly group sessions of health education
Study NCT03586505 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Light exposure
Description: The 6 lights used randomly are :~* 482nm =standard blue light illumination,~* 650nm,~* 675nm,~* 700nm,~* 750nm~* 800nm
Study NCT00462592 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: budesonide
Description: inhaled budesonide turbuhaler 200ug taken 1 puff morning \& 1 puff evening.
Study NCT00462592 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: montelukast
Description: montelukast 5 mg ( \< 15 years) or 10 mg (and matching placebo)will be taken 1 tab in the evening
Study NCT00462592 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: placebo
Description: placebo
Study NCT00462592 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo
Study NCT03738839 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Quantitative Light-Induced Fluorescence
Description: White spot lesion on the tooth surfaces detected with Quantitative Light-Induced Fluorescence Orthodontic Bonding.
Study NCT03738839 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Quantitative Light-Induced Fluorescence
Description: White spot lesion on the tooth surfaces detected with Quantitative Light-Induced Fluorescence Orthodontic Bonding.
Study NCT04447027 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Romidepsin
Description: Romidepsin (12mg/ m2 ) will be administered on days 1 and 10 of each cycle through a peripheral or central intravenous catheter for 6 cycles.
Study NCT04447027 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Lenalidomide will be administered by oral intake in a dose-escalation with a starting dose of 5mg daily, a second dose level of 10mg daily, a third dose level at 15mg daily, and a fourth dose level at 20mg daily on days -7 to day 10 of first cycle. After the second cycle, lenalidomide will be given from day 1 to day 10 in each cycle for up to 6 cycles.
Study NCT04447027 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CC-486 (5-azacitidine)
Description: CC-486 (5-azacitidine) with a dose of 300mg oral intake daily will be given on day 1 to day 10 for 6 cycles.
Study NCT04447027 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone, 40mg, PO, will be given on days 1 and 10 of each cycle.
Study NCT03779750 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: s.creatinine
Description: All ESRD patients on regular hemodialysis in dialysis unit of Assiut university Hospital duing one year. will be subjected to 3- Routine investigations including complete blood picture ,blood urea , s.creatinine,urine analysis , calcium, phosphorus, and parathyroid hormone.
Study NCT01803217 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: pacemaker programming to mode switch to atrial pacing versus atrioventricular hysteresis function
Study NCT01803217 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pacemaker programming to mode switch to atrial pacing versus atrioventricular hysteresis function
Study NCT04019340 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Education
Description: Usual care as described for the CG will also be provided to the IG. Wound size measurement, wound care, and questionnaires will be provided by the institute's nurses. Usual care will be enhanced by a pluridisciplinary educational program
Study NCT01250873 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2216684
Description: po administration
Study NCT01250873 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sertraline
Description: po administration
Study NCT00112528 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bevacizumab
Study NCT00112528 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine hydrochloride
Study NCT00112528 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxaliplatin
Study NCT01559350 — intervention group
Intervention type: PROCEDURE
Intervention: A right gastroepiploic artery in situ grafting
Description: A right gastroepiploic artery in situ grafting in the right coronary artery system during OPCAB
Study NCT01559350 — intervention group
Intervention type: PROCEDURE
Intervention: A saphenous vein grafting
Description: A saphenous vein grafting in the right coronary artery system during OPCAB
Study NCT03738839 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Direct bonding
Description: The patients in the direct bonding group received a bonding procedure with a conventional composite adhesive.
Study NCT03738839 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Direct bonding
Description: The patients in the direct bonding group received a bonding procedure with a conventional composite adhesive.
Study NCT02176863 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Flebogamma 5% DIF
Description: Human plasma-derived immunoglobulin
Study NCT02176863 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Normal saline solution
Study NCT02176863 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Normal saline solution
Study NCT03179020 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Checklist use
Description: Management of the potential donor guided by the use of an evidence-based checklist. This checklist is based on main recommendations of the Brazilian guideline for the management of potential multiple organ donors.
Study NCT03179020 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: Management of the potential donor according usual care.
Study NCT03449329 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: SIP
Description: The intervention group will receive a SIP block
Study NCT03449329 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: SIP
Description: The intervention group will receive a SIP block
Study NCT03121196 — intervention group
Intervention type: OTHER
Intervention: Epices score
Description: Association between EPICES score and the adverse perinatal outcomes will be assessed by quantile regression
Study NCT03050853 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: E-cigarette
Description: The e-cigarette arm will be provided with 8 weeks of free e-cigarettes based on self-report of regular tobacco use. Participants assigned in this arm will be asked to switch combustible tobacco with e-cigarettes. The appeal of e-cigarettes and health impacts will be measured, but we are not targeting quitting combustible tobacco or reducing craving.
Study NCT03847753 — intervention group
Intervention type: OTHER
Intervention: Organic Disorders
Description: Individuals were considered to have a specific mental disorder from the date they received a relevant diagnosis registered in the Danish Psychiatric Central Research Register.
Study NCT01051609 — intervention group
Intervention type: OTHER
Intervention: Grip Strength Measurement
Description: A hand grip strength test will be used to measure and compare baseline and post-AI treatment forearm muscle strength in each hand.
Study NCT01051609 — intervention group
Intervention type: BEHAVIORAL
Intervention: Surveys
Description: Self-administered surveys including Health Assessment Questionnaire Disability Index, CES-D, FACIT-F, PSQI, GAD7, number of minutes of morning stiffness, and questions pertaining to vasomotor symptoms will be used in this study to assess for presence, severity, characteristics, and associations of AI-associated musculoskeletal symptoms.
Study NCT01051609 — intervention group
Intervention type: OTHER
Intervention: Blood Collection
Description: A set of blood markers will be assayed at baseline, 6 months, and 12 months.